Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Report ID: GMI1949

Summary Methodology

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market size is projected to experience significant growth from 2017 to 2024.

Human immunodeficiency virus therapeutics market size should witness tremendous growth, owing to the sprouting incidence of HIV infections. The growing youth-obsessed culture across globe is mostly under the vague of HIV due to unprotected sexual practices coupled with the dearth of awareness concerning transmission risk factors as well as exposure to contaminated and infected needles or syringes. The collaborative efforts of the government and various NGOs to provide help for at-risk individuals with greater receptiveness to disease testing and treatment is the key driving factor of the human immunodeficiency virus therapeutics market. According to American Hospital Association, there were 1.5 million adults and children surviving with HIV/AIDS in North America as of 2016.

High adolescent fertility rate is the opposing effect of extramarital and premarital sex, leading to longer period of sexual activity which increases the risk of infection among the populace. The virus has mostly affected the under developed and the developing countries on a broader scale owing to the scarcity of appropriate treatment, prevention measures and facilities. Approximately 70,000 children and adults are anew infected every year. Nearly 26,000 people in North America die from AIDS every year, with only limited number of patients receive admittance to antiretroviral treatments.

Programs such as Medicare and Medicaid initiated by the U.S. government assists the low-income people in medical billing. The largest HIV specific discretionary grant program is the Ryan White HIV Program which serves as the third biggest source of federal funding for HIV treatment and care in the U.S. The NRTIs (first type of drug available to treat HIV) accounted for the largest market share. It works by blocking the reverse transcriptase enzyme as well as arrests viral replication and impede reverse transcriptase activity.

Integrase inhibitors product segment will witness fastest growth, due to the rise in added integrase inhibitors by key players such as Merck & Co. and Gilead Sciences. These enzymes replicate by inserting viral genomic DNA into the host chromosome. The recent discovery in this segment is the quinoline-based allosteric IN inhibitors (ALLINIs), which potently impairs HIV-1 replication and are presently in clinical trials.

Social stigma, decreasing global funds, discrimination and treatment failures are few factors hindering the growth of the global human immunodeficiency virus therapeutics market. Lack of a definitive treatment is a key health issue and results in a high on-going cost to society.

North America human immunodeficiency virus therapeutics market dominated the industry in 2016 pertaining to the high incidence and prevalence of HIV/AIDS, growing awareness about infection, surging government initiatives and blood donations. The U.S. human immunodeficiency virus therapeutics market is commanded as the greatest national funder of the HIV epidemic globally.

Asia Pacific human immunodeficiency virus therapeutics market will exhibit profitable growth, owing to new developments in treatments. Asian manufacturers prove to be a resilient competition due to their unique patent laws that lead up patent of prerequisite lifesaving medicines. Also, the prices are doomed to decrease the entry of such manufacturers, thereby potentially proliferating the industry with regards to volume.

Key industry players include Gilead Sciences, AbbVie, Bristol-Myers Squibb Company, ViiV Healthcare, and Cipla. Companies focus on innovative product launch and strategic agreements to expand their business portfolio as main strategies. In April 2016, Gilead Sciences, announced the FDA approval of Descovy, a fixed-dose combination for the treatment of HIV, for the treatment of HIV-1 infection.

What Information does this report contain?

Historical data coverage: 2013 to 2015; Growth Projections: 2016 to 2026.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Customize this Report

Pre Book Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability

 Connect with our sales team

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X